Home » Stocks » Nymox Pharmaceutical

Nymox Pharmaceutical Corporation (NYMX)

Stock Price: $2.75 USD -0.28 (-9.11%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 196.87M
Revenue (ttm) 91,000
Net Income (ttm) -13.16M
Shares Out 71.72M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $2.75
Previous Close $3.02
Change ($) -0.28
Change (%) -9.11%
Day's Open 2.77
Day's Range 2.50 - 2.85
Day's Volume 975,660
52-Week Range 1.60 - 4.79

More Stats

Market Cap 196.87M
Enterprise Value 191.78M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 71.72M
Float 38.53M
EPS (basic) -0.19
EPS (diluted) -0.19
FCF / Share -0.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.37M
Short Ratio 8.62
Short % of Float 10.36%
Beta 1.50
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2,163.38
PB Ratio 163.74
Revenue 91,000
Operating Income -13.33M
Net Income -13.16M
Free Cash Flow -7.43M
Net Cash 5.09M
Net Cash / Share 0.07
Gross Margin 63.74%
Operating Margin -14,642.86%
Profit Margin -11,346.60%
FCF Margin -8,164.84%
ROA -107.46%
ROE -223.89%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $2.75
Target: 9.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-61.2%33.48%-21.13%-89.71%-6.39%-12.19%9.32%-1.32%350.33%-
Gross Profit0.
Operating Income-13.33-10.64-13.24-12.87-17.66-4.72-4.88-7.59-9.63-6.51
Net Income-13.16-10.59-13.43-13.11-17.89-4.59-4.91-7.63-9.65-6.54
Shares Outstanding68.8560.4752.6546.1637.4035.2534.1533.1832.7131.94
Earnings Per Share-0.19-0.18-0.26-0.28-0.48-0.13-0.14-0.23-0.30-0.20
Operating Cash Flow-7.43-7.80-6.21-4.50-3.75-5.52-6.72-8.30-10.147.86
Capital Expenditures--0.04-----0.01--0.02-0.01
Free Cash Flow-7.43-7.84-6.21-4.50-3.75-5.52-6.72-8.31-10.167.85
Cash & Equivalents5.247.950.852.020.370.630.301.035.9213.17
Total Debt0.15--0.930.810.72----
Net Cash / Debt5.097.950.851.09-0.44-0.090.301.035.9213.17
Book Value3.457.00-1.25-0.24-2.35-4.58-6.46-7.84-5.60-2.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Nymox Pharmaceutical Corporation
Country The Bahamas
CEO Paul Averback

Stock Information

Ticker Symbol NYMX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NYMX
IPO Date December 1, 1997


Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company operates in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.